How Does a PET Scan Work?
A lung PET scan uses a radioactive tracer, most commonly a glucose-based compound, injected into a vein. Cancerous cells have a higher rate of glucose consumption than any other normal tissue. When the tracer is preferentially absorbed by these active cells, they appear as bright areas on the scan, helping radiologists spot tumors that are not clearly visible on a standard CT.
PET and CT scans are almost universally performed together as a PET-CT. The CT provides detailed structural images showing the size and location of any abnormality. The PET component shows whether cells in that area are metabolically active. Together, they give a far more complete picture than either scan alone.
When Is a PET Scan Used in Lung Cancer?
A PET scan plays a role at three key points in lung cancer management.
Investigating a Suspicious Nodule
When a CT scan reveals a suspicious nodule, a PET scan helps assess whether it is likely malignant. Cancer cells are characterized by rapid, uncontrolled growth, and their high metabolic activity makes them stand out on a PET scan. A nodule showing high tracer uptake (described as "FDG-avid") is significantly more likely to be cancerous than one with low or no uptake. This information helps in deciding if a biopsy is required immediately or not.
Staging the Cancer
Staging determines how far cancer has spread beyond the original tumor. For NSCLC, this means assessing whether cancer has reached nearby lymph nodes or distant organs such as the liver, adrenal glands, or bones. Metabolically active deposits in distant locations and lymph nodes are easily detected by a PET-CT. On a structural CT scan, these regions could look normal. As a result, staging accuracy is greatly increased by a PET-CT scan.
Monitoring Treatment Response
Once treatment has begun, whether chemotherapy, targeted therapy, or immunotherapy, a follow-up PET scan can assess response. If the tumor has responded, its metabolic activity will decrease, making it appear less bright compared to a baseline scan. This allows oncologists to evaluate treatment response earlier than CT alone and to adjust the plan if needed.
What to Expect During a Lung PET Scan
- The tracer is injected through a vein, typically at the inner elbow. Patients then wait around one hour for tracer absorption.
- The procedure takes about 30 to 90 minutes, during which the patient must lie still; movement can blur images and reduce accuracy.
- Preparation requires fasting for four to six hours beforehand, though water is permitted. People taking insulin for diabetes require special preparation, as blood glucose must be well-controlled typically below 150 mg/dL, for results to be reliable.
- All medications should be disclosed to the medical team, as some can interfere with tracer uptake.
Risks and Safety
The radiation from a PET scan is low but is more than twice that of most standard CT scans. The tracer clears naturally from the body within hours. Women who are pregnant or breastfeeding should inform their doctor before having a PET scan. Rarely, some patients can experience allergic reactions to the tracer. Moreover, some patients notice mild pain or swelling at the injection site, which resolves quickly. No recovery time is needed.
Understanding PET Scan Results
PET scan results are interpreted by a radiologist alongside the patient's broader clinical picture. Abnormal tracer uptake does not automatically mean cancer infection, and inflammation can also cause elevated metabolic activity and false-positive results. Equally, some early-stage or slow-growing tumors may show lower activity. This is why biopsy remains essential for any definitive diagnosis.
Normal results mean no abnormal metabolic activity was detected. Abnormal results may indicate cancer in the lungs or distant organs, active infection, or inflammatory conditions.
Conclusion
A PET-CT scan gives medical professionals a unique "functional" map of the body that shows not only the location of a tumor but also its level of activity. The detailed information is crucial for correctly diagnosing the disease and selecting the best course of treatment. Although it is an effective tool for tracking development, it functions best when combined with biopsies and clinical knowledge in a broader diagnostic context. In the end, this technology provides a clearer way forward by assisting in the replacement of uncertainty with an accurate, data-driven care plan.
